ACTH(4-10) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
The three substrates of this enzyme are the plant steroid curbitacin b, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are dihydrocucurbitacin b, and oxidised NAD+. The enzyme can use nicotinamide adenine dinucleotide phosphate as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 23,24-dihydrocucurbitacin:NAD(P)+ Delta23-oxidoreductase. This enzyme is also called NAD(P)H: cucurbitacin B Delta23-oxidoreductase. It contains manganese.
Super League successfully attracted eight of the ARL clubs. In the 1995 State of Origin series, the ARL forbade the players of those eight clubs from participating in the interstate competition. However, those clubs were allowed to participate in the premiership seasons of 1995 and 1996, while the ARL fought in the courtroom to stop the Super League competition from eventuating. However, Super League conducted a rival competition in 1997. Both the ARL and Super League competitions ran parallel to each other that year. At the close of the season, despite having the financial backing of Optus, the ARL decided that it could not survive if two competitions were run and undertook moves to approach News Corporation and join the national competition that had been created by Super League. As a consequence of the negotiations that followed, the National Rugby League was formed before the 1998 season from the ARL and Super League competitions. From 1998 to 2012, the National Rugby League Partnership, a power-sharing arrangement between News Corporation and the Australian Rugby League (ARL), ran the National Rugby League competition as a consequence of the Super League war. Between the 1998 season and the first few months of the 2012 season the ARL had six out of twelve seats on the NRL Partnership board. In 2012 News Limited exited the partnership on condition that the ARL was restructured with an independent board. The ARL was renamed as the Australian Rugby League Commission and restructured on 10 February 2012 and took control of the National Rugby League competition.
== Disadvantages == Handling of small quantities is not always simple. Higher accuracy of weighing is necessary (e.g. use of accurate balance). Sample surface preparation can have a major impact on measurement results.
Sources: en.wikipedia.org
== Newtonian vs Non-Newtonian fluids == A Newtonian fluid (named after Isaac Newton) is defined to be a fluid whose shear stress is linearly proportional to the velocity gradient in the direction perpendicular to the plane of shear. This definition means regardless of the forces acting on a fluid, it continues to flow. For example, water is a Newtonian fluid, because it continues to display fluid properties no matter how much it is stirred or mixed. A slightly less rigorous definition is that the drag of a small object being moved slowly through the fluid is proportional to the force applied to the object. (Compare friction). Important fluids, like water as well as most gasses, behave—to good approximation—as a Newtonian fluid under normal conditions on Earth. By contrast, stirring a non-Newtonian fluid can leave a "hole" behind. This will gradually fill up over time—this behavior is seen in materials such as pudding, oobleck, or sand (although sand isn't strictly a fluid). Alternatively, stirring a non-Newtonian fluid can cause the viscosity to decrease, so the fluid appears "thinner" (this is seen in non-drip paints). There are many types of non-Newtonian fluids, as they are defined to be something that fails to obey a particular property—for example, most fluids with long molecular chains can react in a non-Newtonian manner.
Through the use of a piston in a cylinder this pump creates pressure by using a one way valve and a piston that is controlled by the handle. The Bicycle pump is a vertical hand pump that is used to inflate bicycle tires. these pumps are very common and can be used to inflate many things with the use of an adapter. Diaphragm Pumps
The HAIR-AN syndrome is a rare subtype of polyendocrine metabolic ovarian syndrome (PMOS) characterized by hyperandrogenism (HA), insulin resistance (IR) and acanthosis nigricans (AN). The symptoms of the HAIR-AN syndrome are largely due to severe insulin resistance, which can be secondary to blocking antibodies against the insulin receptor or genetically absent/reduced insulin receptor number/function. Insulin resistance leads to hyperinsulinemia which, in turn, leads to an excess production of androgen hormones by the ovaries. High levels of androgen hormones (hyperandrogenism) in females causes excessive hair growth, acne and irregular menstruation. Patients with both underlying mechanisms of insulin resistance may have more severe hyperandrogenism. Insulin resistance is also associated with diabetes, heart disease and excessive darkening of the skin (acanthosis nigricans)
Ben Howlett (born 21 October 1988) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Howlett was selected by Essendon with pick 30 in the 2010 rookie draft, as a 21-year-old from Peel Thunder in the West Australian Football League. His final season with Peel Thunder saw him claim the club's best and fairest award. He was promoted to Essendon's senior list in the 2010 season. Howlett, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for one season which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. Howlett was delisted at the conclusion of the 2017 AFL season. He returned home to WA and signed with the club he was originally drafted from, Peel Thunder in the WAFL, for the 2018 season. In 2019, Howlett was named captain of the club, taking over from dual premiership captain Gerald Ugle. In Round 9 of the 2021 WAFL season Howlett played his 100th game for Peel Thunder against Swan Districts before announcing his retirement from WAFL footy at the end of that season.
Sources: en.wikipedia.org
==== Effectors ==== Pseudomonas syringae isolates carry a range of virulence factors called type III secretion system (T3SS) effector proteins. These proteins primarily function to cause disease symptoms and manipulate the host's immune response to facilitate infection. The major family of T3SS effectors in P. syringae is the hrp gene cluster, coding for the Hrp secretion apparatus.
While the pharmacokinetic profile of pregabalin results in few direct drug-drug interactions, the pharmacodynamic risk of additive CNS and respiratory depression with other depressant substances represents the primary clinical concern in its use alongside other medications.
=== Ovarian cancer and other === In 2008, the submission was announced of a registration dossier to the European Medicines Agency and the FDA for Yondelis when administered in combination with pegylated liposomal doxorubicin (Doxil, Caelyx) for the treatment of women with relapsed ovarian cancer. In 2011, Johnson & Johnson voluntarily withdrew the submission in the United States following a request by the FDA for an additional phase III study to be done in support of the submission. Trabectedin is also in phase II trials for prostate, breast, and paediatric cancers.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.